What is HC Wainwright’s Estimate for IOVA Q1 Earnings?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Iovance Biotherapeutics in a report released on Tuesday, February 24th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings of ($0.15) per share for the quarter. The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.54) EPS and FY2027 earnings at ($0.28) EPS.

Several other analysts have also issued reports on IOVA. Barclays raised their price target on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an “overweight” rating in a research report on Wednesday. Citizens Jmp upgraded Iovance Biotherapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 target price for the company in a research note on Wednesday. Chardan Capital decreased their price target on shares of Iovance Biotherapeutics from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, The Goldman Sachs Group restated a “sell” rating and issued a $2.00 price objective on shares of Iovance Biotherapeutics in a research note on Thursday, February 5th. Six analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Iovance Biotherapeutics has an average rating of “Hold” and an average target price of $9.33.

Iovance Biotherapeutics Trading Up 1.8%

Shares of IOVA stock opened at $3.86 on Thursday. The firm has a market capitalization of $1.59 billion, a P/E ratio of -3.45 and a beta of 0.76. Iovance Biotherapeutics has a 1 year low of $1.64 and a 1 year high of $4.57. The firm’s fifty day simple moving average is $2.72 and its 200 day simple moving average is $2.43.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. Iovance Biotherapeutics had a negative return on equity of 54.54% and a negative net margin of 148.41%.The firm had revenue of $86.77 million for the quarter, compared to analyst estimates of $81.61 million.

Institutional Investors Weigh In On Iovance Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp lifted its position in shares of Iovance Biotherapeutics by 51.5% during the fourth quarter. State Street Corp now owns 20,161,445 shares of the biotechnology company’s stock worth $55,041,000 after purchasing an additional 6,851,486 shares in the last quarter. Palo Alto Investors LP raised its position in Iovance Biotherapeutics by 122.1% in the 3rd quarter. Palo Alto Investors LP now owns 7,618,132 shares of the biotechnology company’s stock worth $16,531,000 after purchasing an additional 4,188,803 shares during the last quarter. HRT Financial LP lifted its holdings in Iovance Biotherapeutics by 1,078.3% during the 4th quarter. HRT Financial LP now owns 4,356,010 shares of the biotechnology company’s stock worth $11,891,000 after buying an additional 3,986,314 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Iovance Biotherapeutics by 202.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company’s stock worth $19,239,000 after buying an additional 3,869,617 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Iovance Biotherapeutics by 13.1% in the 4th quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company’s stock valued at $74,275,000 after buying an additional 3,148,096 shares during the last quarter. Institutional investors and hedge funds own 77.03% of the company’s stock.

Trending Headlines about Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Q4 / FY results beat expectations — Iovance reported Q4 product revenue of ~$87M (30% growth Q/Q) and full‑year revenue up ~61% to ~$264M; GAAP EPS was less negative than expected (Q4 EPS roughly -$0.18 vs. consensus -$0.22). Investors are treating the print as evidence that Amtagvi commercial sales and the company’s growth trajectory are real. IOVA Beats on Q4 Earnings & Sales
• Positive Sentiment: Pipeline and development catalysts — the stock popped on 50% ORR data and Iovance’s plan for a registrational sarcoma study, reinforcing upside from clinical progress beyond commercial sales. That data-driven message contributed materially to today’s buying. Pipeline Progress & ORR Data
• Positive Sentiment: Analyst upgrades and estimate lifts — HC Wainwright raised FY2026/FY2027 EPS assumptions and maintains a Buy/$9 target; Citizens JMP upgraded Iovance to Outperform. Upgrades and higher price targets amplify demand from institutions and momentum traders. Raised to Outperform at Citizens Jmp
• Positive Sentiment: Manufacturing/commercial ramp explained — reporting and coverage highlighted the Philadelphia factory ramp as a key reason sales can scale, reducing execution risk around supply and supporting the narrative that Iovance is transitioning from pure pipeline to a commercial-stage company. Philadelphia Factory Explains Surge
• Neutral Sentiment: High trading and options activity — unusually large options and stock volume signaled speculative interest and positioning around the earnings/catalyst news; this can amplify intraday moves but is not a sustained fundamental change by itself. Unusually Large Options Volume
• Neutral Sentiment: Management investor outreach — Iovance announced presentations at TD Cowen and Barclays conferences (early March), which could provide additional color but are routine post‑earnings investor engagement. Conference Presentations
• Negative Sentiment: Very large and rising short interest — short interest jumped ~24.8% to ~131M shares (~36.9% of float) with a ~14.6 day cover ratio, leaving the stock vulnerable to volatility and squeezes; this elevated shorting is both a risk (pressure on future upside if sentiment reverses) and a potential amplifier of rapid moves. (data reported 2/25)

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.